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ABSTRACT 
Objective: The evolution of antimicrobial resistance is a universal obstacle that necessities the innovation of more effective and safe antimicrobial 
alternatives with synergistic properties. The purpose of this study was to investigate the possible improvement of cephalexin antimicrobial 
treatments by loading into chitosan-based nanoparticles, then evaluate their antibacterial and antibiofilm activities as well as determination of its 
cytotoxicity. 
Methods: Chitosan nanoparticles (CSNPs) were prepared by ionic gelation method. Parameters were studied to optimize the particle size of CSNPs 
including pH, stirring rate, homogenization and ultra-sonication time. Size was measured by transmission electron microscope (TEM) and Zeta 
sizer, morphology seen by scanning electron microscope (SEM). Entrapment efficiency, drug loading and drug content were calculated. Stability of 
both plain and loaded chitosan Nano-carriers, Drug release and Kinetics also compatibilities were studied. Antimicrobial activity of CSNPs and 
cephalexin loaded CSNPs were evaluated against 4 Gram-positive and 4 Gram-negative standard and clinical isolates by microdilution method, also 
assessment of antibiofilm activity of both formulas was investigated against two biofilm producers clinical isolates by tube assay in addition to 
determination of their cytotoxicity by MTT(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
Results: Chitosan nanoparticles and its loaded antibiotics proved compatible combination with small Zeta size, suitable Zeta potential, maximum 
EE% and drug-loading capacity, sustained controlled release properties followed diffusion kinetic model and six month stability studies. Cephalexin 
loaded CSNPs showed better antimicrobial activity than plain CSNPs. Synergistic effects were found against S. aureus (ATCC 25923), B. subtilis 
(ATCC 9372), S. epidermidis, E. faecalis, P. aeruginosa (ATCC 29853) in addition to two carbapenem resistant isolates k. pneumoniae and E. coli. Also 
cephalexin loaded CSNPs exhibited antibiofilm activity against E. faecalis clinical isolate. Even though, cephalexin loaded CSNPs exhibited significant 
antibacterial activity, it showed less toxicity against mammalian cells, it had IC50 equal to 231.893 and did not exhibit any cytotoxicity against the 
WI-38 fibroblast cells at concentration 23.4
Conclusion: Cephalexin loaded CSNPs possessed good stability and sustained release effect in addition to its antimicrobial, antibiofilm activities and 
reduced cytotoxicity. 
 µg/ml. 
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The evolution of microbial resistance against different classes of 
antibiotic has attracted more attention and forced researchers to 
formulate innovative antimicrobial agents that exhibit efficient 
antimicrobial activity against the frequently increasing multidrug 
resistant pathogens [1]. Limited cellular penetration reduces the 
effectiveness of many antimicrobial treatments and minimizes its 
effectiveness against different bacterial infections [2]. Chitosan is a 
copolymer composed of N-acetyl glucosamine and glucosamine units 
[3]. It has been used as antibacterial and antifungal material [4, 5]. 
There are several mechanisms that explain the antibacterial activity 
of chitosan, the most acceptable one assumes that chitosan binds to 
the negatively charged bacterial surface disturbing the cell 
membrane and altering its permeability then attach to DNA causing 
inhibition of DNA replication and consequently cell death [6]. 
Additional probable mechanism is selectively binding of chitosan as 
chelator to cellular trace elements causing toxicity and growth 
inhibition [7]. Chitosan exhibit its antibacterial activity only in acidic 
pH. Several factors affect the antibacterial activity of chitosan 
including degree of polymerization, molecular weight, chitin type, 
solvent and pH of the solution [8, 9]. Some studies have revealed 
that chitosan display higher antibacterial activity against Gram-
positive bacteria more than Gram-negative; meanwhile other studies 
have reported its higher antibacterial against Gram-negative strains 
[10]. Cell wall in Gram-positive bacteria composed of thick layer of 
peptidoglycan polymer with integral protein channels that allow 
foreign molecules to diffuse into the cell without any difficulty [11, 
12]. Conversely, it has been proved that hydrophilicity in Gram-
negative bacteria is considerably higher than in Gram-positive 
bacteria, making them more sensitive to effect of chitosan [13]. 
Moreover chitosan facilitates the transport of molecules across 
plasma membranes as it is a mucoadhesive polymer [14-16]. 
Chitosan nanoparticles(CSNPs) provide higher affinity within 
bacterial cells for a quantum-size effect, due to the larger surface 
area of the CSNPs, which could be tightly adsorbed onto the surface 
of the bacterial cells to disrupt the membrane, leading to the leakage 
of intracellular components and thus bacterial death [17, 18]. CSNPs 
have been used a successful drug carriers owing to their transfer 
efficiency in the cells as reported in several studies [19]. As drug 
carrier CSNPs offer many advantages as it is biocompatible and 
biodegradable safe material, available in a wide range of molecular 
weights, water-soluble polymer [20] has absorption promoting 
effect that prolongs the contact time between substrate and cell 
membrane in addition to its diverse non-invasive administration 
routes as oral, nasal, and ocular rout [21]. Cephalexin is β-lactam 
antibiotic that preserves antibacterial activity against both Gram-
positive and Gram-negative bacteria [22]. It has been efficiently 
applied in management of bacterial infections in upper and lower 
respiratory tract, eye and ear, urinary tract, bones and joints as well 
as skin infection [23]. The aim of the current study was to apply 
nanotechnology in formulation and delivery of cephalexin as a broad 
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spectrum antibiotic and evaluate its antibacterial activity against 
standard and multidrug resistant strains In addition to study all 
criteriaof unloaded or loaded nano-carrier with cephalexin, 
antibiofilm activity and cell toxicity.  
MATERIALS AND METHODS 
Mterials 
Chitosan (degree of deacetylation of 93%) and sodium 
tripolyphosphate (STPP) were purchased from (Sigma-Aldrich St. 
Louis, MA, USA). Sodium hydroxide, Methyl alcohol, ethyl alcohol 
and acetic acid were purchased from El-Nasr Company for chemicals 
(Cairo, Egypt). And. Cephalexin antibiotic was a gift from Simco 
Shefa pharmaceutical company (Giza, Egypt). MTT solution was 
purchased from (Bio Basic Canada Inc, Ontario, Canada). All 
chemicals were with high quality grade and used without further 
purification. Mueller-Hinton Agar (MHB), Mueller-Hinton Broth 
(MHB) and brain heart infusion broth (BHIB) and brain heart 
infusion agar (BHIA) were obtained from (Lab M Ltd Lancashire, 
UK). Medium used for cell culturing and cytotoxicity assay was 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher 
Scientific, Waltham, MA, USA) supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Trade Scientific, Sigma-Aldrich, St Louis, MO, 
USA) in addition to penicillin and streptomycin (100 units/ml) 
(Sigma-Aldrich St. Louis, MA, USA). 
Bacterial isolates  
Standard bacterial strains obtained from The Egyptian Company for 
the Production of Sera and Vaccines (VACSERA, Dokki, Giza) and The 
Regional Center for Mycology and Biotechnology, (Al-Azhar 
University Cairo, Egypt). and multidrug resistant clinical isolates 
were selected; they include Staphylococcus aureus (ATCC 25923), 
Bacillus subtilis (ATCC 9372), Staphylococcusepidermidis 
and Enterococcus faecalis as representatives for Gram-positive 
bacteria and Escherichia coli (ATCC 25922), Pseudomonas 
aeruginosa (ATCC 29853), klebsiella pneumoniae as well 
as Escherichia coli clinical isolates as representatives for Gram-
negative bacteria. Both klebsiella pneumoniae as well as Escherichia 
coli clinical isolates were identified as carbapenem resistant by 
phenotypic and molecular method via PCR detection of bla NDM-1
Methods 
 
gene that indicates production of metallo-beta-lactamases [24].  
Preparation of chitosan nanoparticle 
Plain chitosan nanoparticles and cephalexin loaded nanoparticles 
were prepared based on the modified ionotropic gelation with 
minor modification [25, 26]. Chitosan was dissolved in aqueous 
solution containing 1% (v/v) acetic acid and leaving it under high 
stirring (1100 r/min) for 2 h. The pH was adjusted to pH 5 with 
0.01N NaOH. STPP as a physical cross linker was dissolved 
separately in deionized water and added to the chitosan solution at a 
drop rate of 12 ml/h at different STPP: chitosan ratios under 
vigorous magnetic stirring at room temperature. The resulting 
suspension was then homogenized at 22000 r/min for 3 min and left 
under ultra-sonication for 45 min. 
Preparation of antibiotic-loaded chitosan nanoparticles  
Different concentrations of the antibiotic were used, cephalexin-
loaded CSNPs were formed spontaneously upon the dropwise 
addition of an aqueous solution of sodium TPP to 20 ml of a 0.2 
% w/v chitosan solutions, containing different five cephalexin 
concentrations (0.05, 0.1, 0.15, 0.2 and 0.25% w/v), with 




Different chitosan concentrations effect (0.1, 0.15 and 0.2) %w/v 
were studied at constant other parameter such as concentration of 
sodium tri polyphosphate 1 mg/ml and pH 5,stirring at 1100 r/min, 
homogenization at 22000 r/min for 3 min and ultra-sonication time 
45 min at room temperature. 
Sodium tri-poly phosphate concentration 
The effect of concentrations of sodium tri poly phosphate (0.5, 1, and 
1.5) mg/ml was studied at constant other parameters: concentration 
of chitosan at (0.2) %w/v, at pH 5, stirring at 1100 r/min, 
homogenization at 22000 r/min for 3 min and ultra-sonication time 
45 min at room temperature. 
Antibiotic loaded chitosan nanoparticles 
Different cephalexin concentrations loaded in chitosan 
nanocomposite were studied (0.05%w/v, 0.1%w/v, 0.15%w/v, 
0.2%w/v and 0.25%w/v). An optimized formulation was chosen 
dependent on the set criteria i.e. suitable Nano size, polydispersity 
(PDI) and maximum entrapment efficiency. 
Characterization of chitosan nanoparticles and its loaded 
Differential scanning calorimetric (DSC) 
DSC interactions are typically ascertained as the elimination of 
endothermic peaks, appearance of recent peaks, difference in peak 
height and its onset, peak temperature/melting points and relative 
peak area, or enthalpy. It likewise gives data regarding drug 
excipient compatibility and development of new substance. Thermal 
analysis was used in order to elucidate any interactions between 
cephalexin and investigated polymer. DSC was carried out using 
Shimadzu, DSC 60 thermal analyzer with a liquid nitrogen cooling 
accessory. The analysis was performed under purge of dry nitrogen 
gas (40 mL/ min−1). A sample of 2–5 mg was placed in an aluminum 
crucible cell and was firmly crimped with the lid to provide an 
adequate seal. The samples were heated from ambient temperature 
to 400C ° at a preprogrammed heating rate of 10C °/ min−1
Fourier transform infrared analysis 
. All 
samples were analyzed in the same manner. 
FTIR is used to study the molecular interaction between formulation 
components. The infrared spectrum of previously lyophilized 
cephalexin CSNPs sample was studied. FTIR spectra of the chitosan, 
STPP, free cephalexin, physical mixture and lyophilized cephalexin 
CSNPs were recorded by using an FT-IR spectrophotometer (Nexus 
670, Nicolet, USA) in the region of 4000-400 cm-1 with spectra 
resolution of 4 cm-1
Optical microscopy 
.  
A thin layer of formed colloidal dispersion were spread on a slide, 
diluted with a small drop of deionized water then dried. The nature 
of vesicle observed and the presence of drug crystals which are 
insoluble were focused under light microscope at various 
magnification powers (10×and40×). Photomicrographs were taken 
using Fujifilm Finepix F 40 fd (8.3 MP) digital camera with 3 × 
optical zoom. [25]. 
Size analysis and zeta potential 
The particle size and polydispersity index of formulated CSNPs 
either drug loaded or unloaded was determined by using Zeta sizer 
by dynamic light scattering (Nano ZS, Malvern, and Worcester-shire, 
UK). The ionic potential at the partcles surface called Zeta potential, 
and it is measured in millivolts. Zeta potential is a logical term for 
electro kinetic potential in colloidal dispersions and it is the most 
imperative parameter for physical stability of CSNPs. The higher the 
electrostatic repulsion between the particles more is the stability 
[26]. Before measurement samples were dispersed in distilled 
water. Three replicates were measured and values were presented 
as mean±standard deviation (SD). 
Transmission electron microscope 
The morphology and size of the prepared CSNPs formulations was 
investigated by transmission electron microscopy (TEM) HU-12A 
(Hitachi Ltd, Mito, Japan) at the Research Park of Faculty of 
Agriculture, Cairo University. A drop of the dispersion was diluted 
10-fold using deionized water, and then a drop of the diluted 
dispersion was applied to a carbon-coated 300 mesh copper grid 
and left for 1 min to allow some of the CSNPs to adhere to the carbon 
substrate. The remaining dispersion was removed by absorbing the 
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drop with the corner of a piece of filter paper. After twice rinsing the 
grid with deionized water for (3–5 s) a drop of 2% aqueous solution 
of uranyl acetate was applied for 1 s. The remaining solution was 
removed by absorbing the liquid with the tip of a piece of filter 
paper and the sample was air dried [27]. 
Scanning electron microscope 
Scanning electron microscopy (SEM) (Hitachi-S 3400N) was 
performed at the Center of Agriculture Researches, Cairo University. 
It was used to study visualization that provides surface morphology 
and basic composition of sample by emitting electrons [28]. The 
samples were mounted directly onto the SEM using double sided 
sticking tape and were gold spray coated [29]. 
Cephalexin loading and encapsulation efficiencies 
The encapsulation and loading efficiencies of the nanoparticles were 
determined by first separating the nanoparticles from the aqueous 
medium by ultracentrifugation at 15, 000 r/min for 30 min at 4 C 
°(Sigma,3-30KS,Germany), A standard calibration curve of drug was 
plotted for this purpose. The amount of free cephalexin in the 
supernatant was measured using a UV spectrophotometer at 257 nm 
(Shimadzu-UV/800, Japan). The encapsulation efficiencies % of the 
nanoparticles and cephalexin loading % were calculated as follows:  
Encapsulation efficiency % =TP–Tf/TP
Where Tp is the total cephalexin used to prepare the nanoparticles 
and T
 x 100 (1)  
f
Loading efficiency % = T
 is the free cephalexin in the supernatant. 
P–Tf/
Drug content 
Mass of nanoparticles X 100 (2)  
Drug content was determined thrice at weeks 4, 8 and 12 from first 
date of preparation by placing each lyophilized dried formula after 
weighing in 20 ml phosphate buffered saline pH 6.8, followed by 
agitation in an incubator shaker (100 r/min) for 24 h at 37 C °. After 
suitable dilutions drug solubilized was analyzed spectro-
photometrically at λ max 257 nm.  
Release of cephalexin from CSNPs nanocomposites 
The in vitro release refers to the rate of dissolving the drug from an 
intact dosage form fragments or particles. There are two reasons for 
performing in vitro release tests, one of them is to ensure product 
uniformity from batch to batch, and the other reason is to predict 
the rate of drug absorption and/or availability of the drug for 
absorption. In vitro release is more fundamental important than 
disintegration for predicting in vitro drug availability [30]. The in 
vitro release studies of cephalexin loaded CSNPs were carried out in 
USP type II auto sampler dissolution apparatus (Hansen, Germany) 
fitted with eight rotating paddle and vessels. Five concentrations 
formulas were used for release study; the medium employed was 
600 ml of HCl, pH 1.2 for 2 h then changed to phosphate buffer pH 
6.8 at 37°C+0.5 °C. by adding 30 gm of Tri-sodium orthophosphate 
[31], each concentration was repeated thrice. The paddle speed was 
100 r/min. At appropriate intervals(0.5, 1, 1.5 and 2 h) at HCl pH 1.2, 
(0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 
24 h) at phosphate buffer pH 6.8, 2 ml of each sample was taken and 
replaced by fresh dissolution media. The samples were analyzed at 
257 nm by UV-visible spectrophotometer. 
Kinetics of antibiotic’s release  
In order to know the mechanism of drug release from the CSNPs, the 
experimental cumulative release data were fitted on various release 
model commonly used to describe the release kinetics from 
nanoparticles such as First order, second order, Higuchi kinetic 
models, Hixson-Crowell kinetic models, diffusion and Baker model at 
pH 1.2, and 6.8 using multiple linear regression analysis (sigma plot 
11 software). The release rate constant (K) and correlation 
coefficient (r2) close to unity was taken as order of release. The 
following models were fitted: log cumulative % drug remaining 
versus time (first order kinetic model), log concentrations plot 
versus time is a straight line with k equal slope of the line (second 
order kinetic model), cumulative % drug release versus square root 
of time (Higuchi model), cube root of the initial concentration minus 
cube root of percent remaining versus time (Hixson-Crowell 
models), the release rate constant, k, corresponds to the slope and 
drug release studies were plotted as [d (Mt/M∞)]/dt with respect to 
the root of time inverse. (Baker Lonsdale
Stability study 
) [32]. 
Both plain and loaded CSNPs were stability studied. By keeping the 
optimum unloaded formula of CSNPs as cephalexin carriers at two 
different temperature conditions like refrigeration temperature (4C 
°), room temperature (25±2 C °) in aluminum foil sealed glass vials. 
The samples were withdrawn at different time intervals over a 
period of six month and they were observed visually and under 
optical microscope and examined morphologically by TEM for the 
change in consistency and appearance of drug crystals upon storage. 
Also Nano size, PDI and Zeta potential were examined [25]. The 
mean particle size of CSNPs loaded dispersion, surface charge (Zeta 
potential) and PDI was determined by using a Malvern zeta sizer 
(Malvern Instruments, UK) on the spot and monthly for six month. 
The stability of vesicles to retain the drug was assessed, the 
retention of entrapped drug of 0.25%w/v loaded CSNPs formula was 
measured 72 h after preparation and then monthly of 6 mo duration 
[33]. Stability for formulation was defined in terms of retaining its 
initial entrapment efficiency for six months duration. Stable 
formulation was defined by showing high entrapment efficiency 
(>60%) and high drug retention value (>90%) at each time interval, 
also non-significant change in size, PDI and Zeta potential. Drug 
retained in CSNPs= Entrapped Cephalexin after storage/Entrapped 
Cephalexin before storage ×100.  
In vitro evaluation of antibacterial activity  
The antibacterial activity of CSNPs (1250 µg/ml) and cephalexin (250 
µg/ml) loaded CSNPs 1250 µg/ml) were carried out by microdilution 
method for determination of minimal inhibitory concentration (MIC) 
then determination of minimum bactericidal concentration (MBC) and 
compared to cephalexin (1000 µg/ml) as the reference antibiotic. The 
protocol of the studies (REC-FPSPI-11/72) was approved by the 
Research Ethics Committee for experimental and microbiological 
studies at the Faculty of Pharmaceutical Sciences and Pharmaceutical 
Industries, Future University in Egypt.  
Assessment of minimum inhibitory concentration (mic) and 
minimum bactericidal concentration (MBC) 
The MIC was detected by broth microdilution method according to 
Novy et al. [34] with minor modifications. Briefly, 100 L of MHB was 
transferred to each well in 96 microplate then serial two-fold dilution 
with CSNPs, cephalexin loaded CSNPs and cephalexin. Then, 5 L of a 
fresh bacterial culture (final concentration of 1 × 108 CFU/ml) of 
tested microorganism was added. Positive and negative control wells 
(without drugs and bacterial culture respectively) were processed 
along. Microplates were incubated at 37°C for 24 h. The experiment 
was performed in triplicate. MIC was defined as the lowest 
concentration of the formula that inhibits the visible growth of tested 
microorganism. For determination of MBC, 100 L from each well that 
showed no visible growth was inoculated on MHA agar plates; then the 
plates were incubated at 37 ∘C for 24 h. MBC was defined as the lowest 
concentration showing no bacterial growth on agar surfaces. 
The synergy of antibacterial activity is usually expressed by sum of 
Fractional Inhibitory Concentration (FIC) by the following formula:  
FIC (cephalexin) =MIC ofcephalexin loaded in CSNPs 
MIC of cephalexin
 FIC (CSNPs) 
=MIC ofCSNPs load cephalexin 
MIC of CSNPs
 
ΣFIC=FIC of cephalexin+FIC of CSNPs [35]. 
The results were interpretted as follow; a synergistic effect when 
ΣFIC value<1; a commutative effect when ΣFICvalue = 1; an 
indifferent effect when 1<ΣFIC value ≤ 2 and an antagonistic effect 
when ΣFIC value>2 [36].  
Antibiofilm assay  
At first, production of biofilm formation for tested microorganisims 
was detected by inoculation on congo red agar (CRA) (BHI agar 
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supplemented with 5 % sucrose and 0.8% congo red). A single 
colony of all tested bacteria were culturd overnight in the medium 
for 24 h at 37 °C. The plates were inspected for color of the colonies. 
Positive biofilm producers were indicated by black colonies with a 
dry crystalline consistency while non biofilm producers strains 
formed red colonies. 
Antibiofilm assay was performed by tube method according to 
Hasan et al.[37], with a slight modification. Briefly 2 ml of sterilized 
(BHI) media was added to sterilized narrow and small test tubes. 
Then, 50 μl of a fresh culture of selected strains (final concentration 
of 1 × 108
A MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay was performed to determine the cytotoxic effects of 
CSNPs and cephalexin loaded CSNPs on the WI-38 cells (human 
normal embryonic lung-derived fibroblasts) were purchased from 
the ATCC (American Type Culture Collection, CCL-75
 CFU/ml) was added to each. Sub MIC concenterations of 
cephalexin loaded CSNPs and CSNPs were inoculated to each tube. 
Negative and positive controls tubes were processed for each strain 
then all tubes were incubated at 37 °C for 24 h. The formation of 
biofilm in all test tubes was examined at 24 h interval. the tubes 
were decanted and washed with normal saline and dried followed 
by staining with 0.1 % crystal violet then the contents were 
decanted gently. Excess stain was washed with distilled water and 
dried. Biofilm formation was considered positive when visible film 
lined the wall and bottom of the tube. Ring formation at the air 
liquid interface was not indicative of biofilm formation. 
Cell Culturing and MTT cytotoxicity assay 
™). A 96 well 
tissue culture plate was inoculated with 1 X 105 WI-38 cells/ml (100 
µl/well) and incubated at 37°C in supplemented DMEM media to 
develop a complete monolayer sheet. Growth medium was decanted 
from 96 well micro titer plates after confluent sheet of cells was 
formed; cell monolayer was washed twice with wash media. Serial 
two-fold dilutions of CSNPs and cephalexin loaded CSNPs were made 
in DMEM media with 2% FBS (maintenance medium). After that 0.1 
ml of each dilution was tested in different wells leaving 3 wells as 
control, receiving only maintenance medium. Plate was incubated 
for 24 h at 37°C and examined. Cells were checked under inverted 
microscope for any physical signs of toxicity, e. g. partial or complete 
loss of the monolayer, rounding, shrinkage, or cell granulation. MTT 
solution was prepared (5 mg/ml in phosphate buffer saline) then 20 
µl of MTT solution were added to each well. The plate was placed on 
a shaking table (150 rpm for 5 min) to thoroughly mix the MTT into 
the media and incubated at 37°C in 5% CO2
 
 for 1-5 h to allow MTT 
to metabolize. The media were dumped off then the plate was dried 
on paper towels to remove any residue. Formazan (MTT metabolic 
product) was re-suspended in 200 µl DMSO and placed on a shaking 
table (150 rpm for 5 min) to thoroughly mix the formazan with the 
solvent. Optical density was measured at 560 nm using a multiwall 
microplate reader (Synergy HT, BioTek, France,) and background 
was subtracted at 620 nm. Optical density is directly correlated with 
cell quantity. The experiment was performed in triplicate, and the 
result is expressed as the mean±SD [38].  
RESULTS AND DISCUSSION 
Preparation and Characterization of Chitosan Nanoparticles 
 
 
 Fig. 1: Formation of the chitosan-tripolyphosphate complex by ionotropic gelation. (a) Schematic illustration of the chitosan-STPP 
complex and (b) TEM image of chitosan nanoparticles with 35 nm diameter 
 
 
Effect of chitosan concentration on nanoparticles size 
By studying the chitosan concentration effect (0.1, 0.15 and 0.2) % 
w/v, while constant other parameter such as concentration of 
sodium tri polyphosphate 1 mg/ml and pH 5, 1100 r/min stirrer 
rate, 22000 r/min homogenization for 3 min and ultra-sonication 
time 45 min., It was observed that with increase in the concentration 
of chitosan the appearance of the solution changed from clear 
viscous liquid to opalescent fluid and then precipitated the solution 
became opalescent indicating the formation of Nano chitosan with 
smallest Nano size ranged (23-35 nm). From table 1 it is obvious 
that by increasing the chitosan concentration from 0.1 to 0.2 % w/v 
at a constant STPP concentration (1 mg/ml), the size of 
nanoparticles measured by TEM were decrease. Nano sizes of 
particles are more favorable at the chitosan concentration of 0. 2 
%w/v was (23-35 nm) with mean of 33.6±17.9 than 0.15 %w/v (34-
71 nm) with mean of 40.2±25.5 and 0.1 %w/v (43-95 nm) with 
mean of 38.1±15.4. 
 
Table 1: Effects of different chitosan concentrations on Nano-carriers optimization (n=3) parameters 
















 n=number of determination; SD=Standard Deviation 
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Effect of STPP concentration on nanoparticles size 
The effect of concentration of sodium tri poly phosphate (0.05, 1 and 
1.5) mg/ml was studied at constant other parameters: concentration 
of chitosan at (0.2) %w/v, at pH(5), 1100 r/min stirrer rate, 22000 
r/min homogenization for 3 min and ultra-sonication time 45 min. 
Sodium tri poly phosphate (STPP) a major ingredient for cross 
linking has a pronounced effect on the properties of chitosan 
dispersion, the concentration of STPP was increased gradually, the 
solution became opalescent indicating the formation of Nano 
chitosan. It was observed from table 2 that with increase in 
concentration of STPP, the particle size of chitosan nanoparticle 
increased measured by TEM, concentration of STPP above 1 mg/ml 
resulted precipitation. The precipitation at excessively higher 
concentration of STPP may be attributed to the aggregation of 
chitosan molecules due to excessive cross linking through STPP 
bridging. By increasing the STPP concentration from 0.5 to 1.5 g/ml 
at a constant chitosan concentration (0.2 %w/v), the mean size of 
chitosan nanoparticles changed from 8.4±2.6 nm at (0.5 mg/ml) to 
39.3±14.8 nm at (1.5 mg/ml) but the more favorable mean size was 
15.4±12.8 nm at (1 mg/ml) of STPP which have a good distribution 
for a nanoparticle all over the solution i.e. mean PDI was 0.27±0.008. 
 
Table 2: Effects of different STPP concentrations on Nano-carriers optimization parameters (n=3) 
STPP conc. mg/ml  TEM size d. nm   Malvern Zeta sizer d. nm  PDI  Zetapotential±SD mV 















 n= number of determination; SD=Standard Deviation 
 
Effect of cephalexin concentrations 
Ionotropic gelation was successfully preparing CSNPs; this 
technique relies on the interaction between negatively charged 
polyanions and positively charged chitosan polymer to form 
covalently cross-linked networks. Table 3 clarify the effect of 
cephalexin concentrations on Nano carries, the mean size 
distribution was vary according to %w/v antibiotic loaded. The 
mean size measured by Malvern Zeta sizer was 194.7±33.5 nm with 
0.05 %w/v, 200.7±36.2 nm with 0.1%w/v, 307.1±39.5 nm with 0.15 
%w/v, 205.7±24.1 nm with 0.2 %w/v and 218.5±83.8 nm with 0.25 
%w/v with a fairly monodisperse polydispersity index which almost 
0.2. Nanoparticles carried a positive charge zeta potential ranged 
between 17.3±3.6 to 21.3±3.3 mV. Drug Encapsulation efficiency 
percent was high with all loading %w/v ranged from 
89.714±2.231% to 95.305±2.013%. Drug loading % was increased 
by increasing loading %w/v. Drug loading was 12.930±0.236% with 
0.05 %w/v loading, 23.294±1.071% with 0.1%w/v, 29.915±0.910% 
with 0.15 %w/v, 37.156±0.436 % with 0.2%w/v and 43.32±0.914% 
with 0.25%w/v. 
 
Table 3: Effects of different Cephalexin concentrations on Nano-carriers optimization (n=3) parameters 


























 n=number of determination; SD= Standard Deviation 
 
 
Fig. 2: DSC Thermogram, (a) cephalexin, (b) Chitosan, (c) STPP, (d) physical mixture, (e) cephalexin-CSNPs nanocomposite 
 
Differential scanning calorimetric (DSC) 
As shown in fig. 2, DSC heat flux versus temperature curve for 
cephalexin showed a broad endothermic melting process at 103 °C, 
while a sharp positive exothermic transition beak around 188.44 °C. 
Broad endothermic beak at 296.52 °C was indicating cephalexin 
decomposition. Endothermic peak at 87.51 °C was indicating glass 
transition temperature of chitosan and dehydration, while exothermic 
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melting temperature at 42.90 °C was shown by endothermic peak. 
Clear glass transition endothermic peak was observed at 199.73 °C. 
The physical mixture shows similar peaks support physical 
compatibility. The water-holding capacity of cross-linked chitosan 
with STPP at pH 5 was found to be more (ΔH 439.56 J/g) compared 
with that of plain chitosan, the cross-linking of chitosan with STPP 
modifies the crystalline nature of chitosan. The hydrophilicity of cross-
linked chitosan is higher at pH 5, which might be responsible for its 
increase in the water holding capacity. On the basis of these results it 
can be stated that increase in the polar groups and reduction in 
crystalline domains caused an increase in the water-holding capacity 
of cross-linked chitosan. These results are in agreement with the work 
done by Kittur et al. [39], where they studied the thermal behavior of 
chitosan and their carboxymethyl derivatives showing that the 
increase in the N-deacetylation and carboxymethylation of chitosan 
led to increase in the water-holding capacity. Owing to the differences 
in the chemical characteristics, changes in the exothermic peak of 
chitosan and cross-linked chitosan were also observed. The presence 
of free unsubstituted amine groups showed higher ΔH values. As the 
free amine groups in cross-linked chitosan with STPP at pH 5 are 
more, the ΔH value found was 31.11 J/g, the energy required was 
19.50 J/g. Characterization of cross-linked chitosan by DSC provided 
the evidence of reduction in crystallinity and increase in hydrophilicity 
after cross-linking with STPP pH 5. 
Zeta potential 
Zeta potential is identified with the charge on the surface of the 
molecule, thus impacts an extensive range of properties of colloidal 
materials, for example, their stability, interaction with electrolytes 
and suspension rheology. Literature suggested that zeta potential 
value should lie in the range of-20 mV to+30 mV. Zeta potential was 
found to be ranged from 10.876±2.935 mV to 24.1±5.392mV that 
indicates the formation of stable formulation. In general positive 
Zeta potential values of CSNPs, due to carboxyl group of chitosan.  
FTIR 
The FTIR spectra are shown in fig. 3. The spectrum obtained for 
cephalexin monohydrate sample shows major bands at 3414 cm-1, 
3275 cm-1, 2607 cm-1, 1758 cm-1, 1689 cm-1 and 1593 cm-1, similar to 
that reported by Di Stefano et al. [40]. When compared with the 
standard cephalexin monohydrate (PSA), the capsule (CCC), the raw 
powder (PMD) and the suspension ample (CSM) had the same FTIR 
profile although CSM was amorphous. The broad band at ~2600 cm-
1 due to stretching mode of NH3+confirming the presence of 
Zwitterionic form. Chitosan showed characteristic peaks in IR 
spectrum which confirms its saccharide structure. These peaks are 
obtained at 1153, 1384, 1616, and 894 cm−1. Characteristic strong 
amino peak was found at around 3545 cm-1, 2360 cm-1 and 2017 cm-
1 which are assigned to amide I and II bands. The peak at 1990 cm−1 
in C3 is the joint contribution of bend vibration of OH and CH. The 
free aldehyde group absorption appearing at 1616 cm−1, chitosan 
hydrogen bonded hydroxyl group gave a peak at 3417 cm−1. The 
broadness of the peak is due to presence of water and subsequent 
hydrogen bonding. For STPP, the peak between1091 and 1215 cm−1 
region refers to P˭O gr oup present in phosphate [41]. The peak at 
1095 cm−1, on the other hand, could be attributed to P–O–R vibration 
of the phosphate group. The FTIR spectra of chitosan and cross-
linked chitosan are shown in fig. 3, a characteristic band at 3429 cm–
1 is attributed to–NH2 and–OH groups stretching vibration and the 
band for amide I at 1616 cm–1 is seen in the infrared spectrum of 
chitosan. Whereas in the FTIR spectra of cross-linked chitosan the 
peak of 1616 cm–1 disappears and 2 new peaks at 1639 cm–1 and 
1562 cm–1 appears. The disappearance of the band could be 
attributed to the linkage between the phosphoric and ammonium 
ions. The crosslinked chitosan also showed a peak for P = O at 1384 
cm–1
  
. Some researchers [42-44], observed similar results in their 
study of formation of chitosan nanoparticles and chitosan film 
treated with phosphate. 
 
Fig. 3: FTIR Diagram, (a) cephalexin, (b) Chitosan, (c) STPP, (d) physical mixture, (e) cephalexin-CSNPs nanocomposite 
 
Optical microscopy 
Examination of both plane and loaded CSNPs with different 
antibiotic concentrations % w/v, were showed small vesicles with 
uniform surface area fig. 4 a. shown vesicles of optimized chitosan 
(CS) Nano-carriers loaded with 0.25 % w/v.  
Size analysis  
The size of nanoparticles could be varied by changing the chitosan 
concentrations %w/v. Measuring Nano diameter by Zeta sizer was 
222.8±99.7 d. nm with CS 0.1%w/v, 203.7±42.7 d. nm with CS 0.15% 
w/v and 176.6±69.9 d. nm with CS 0.2%w/v. Polydispersity index was 
0.2 and Zeta potential ranged from 13.3±0.1 mV to 17.8±4.2 mV as 
shown in table 1. Changing the amount of STPP sequencing Nano size 
diameter was changed, it was 252.3±126.4 d. nm with 0.5 mg/ml cross 
linker concentration, 157±17.5 d. nm with 1 mg/ml and 475.8±79.8 d. 
nm with 1.5 mg/ml STPP. Polydispersity index was ranged from to 0.2 
to 0.4 and Zeta potential ranged from10.8±2.9 mV to 24.1±5.3 mV as 
shown in table 2. Different %w/v of cephalexin loaded changing Nano 
size as was explained and shown in table 3. Average vesicle's size of 
CSNPs measured by Zeta sizer was found to be higher than measuring 
with TEM. This is may be attributed to the difference in the principles 
underlying these techniques. 
Transmission electron microscope 
Fig. 4 showed TEM image indicate homogenous small-sized Nano 
spherical structures with smooth morphology. The unloaded Nano 
particles also exhibited rigid surface with higher reliability, due to 
the interfacial interaction between STPP and polymer chain. The 
average diameter of plane CSNPs with different CS concentrations 
are ranged from 33.632±17.966 nm to 40.271±25.526 nm. Nano-
carriers with different STPP concentrations ranged in diameter from 
8.417±2.669 nm to 39.341±14.811 nm. The TEM image is in good 
agreement with that in the literature. 
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Fig. 4: a. optical view of loaded vesicles. b, c and d TEM image of unloaded vesicles with different CS concentrations, e, f and j TEM image of 
unloaded vesicles with different STPP concentrations 
 
   
Fig. 5: SEM image of cephalexin-CSNPs nanocomposite 
 
Scanning electron microscope 
The surface morphology of the lyophilized dried cephalexin-CSNPs 
nanocomposite, as studied by field-emission scanning electron 
microscopy, is shown in fig. 5. The nanocomposites appear to have 
an agglomerated structure with a non-uniform size. This aggregation 
could be a result of the strong inter-and intra-molecular hydrogen 
bonding between nanoparticles. 
Cephalexin loading and encapsulation efficiencies % 
Percentage encapsulation efficiency was measured by “centrifuge 
method”, in which unentrapped drug was calculated spectro-
photometrically. All loaded antibiotic formulations gave excellent 
percentage entrapment efficiency as shown in table 3. EE% was 
90.517±1.660 for 0.05%w/v loaded antibiotic, 92.699±3.674 for 
0.1% w/v, 89.714±2.231 for 0.15%, 92.892±1.090 for 0.2%w/v and 
95.305±2.013 for 0.25% w/v. Zeta size, PDI, Zeta potential and % 
drug loading were measured for each drug loading. 
Drug content 
Each of the studied three samples was loaded with 0.25% w/v 
antibiotic and showed high drug content. At week 4 drug contents 
was 96.35%, at week 8 it was 96.24% and at week 12 drug contents 
was 96.27% with average equal to 96.289%. The predominant 
influencing factor could be good percent entrapment efficiency, 
narrow size distribution of the prepared nanoparticles and the 
nanoparticles were fairly stable. 
Release of cephalexin from CSNPs nanocomposites 
Fig. 6 presents cephalexin % release profile up to 26 h. The CSNPs 
showed initial releases of cephalexin in acidic medium pH 1.2 
ranging from 20 up to 40% for all concentrations were used in the 
release study. This initial release of cephalexin was forced by some 
antibiotic localized on the surface of CSNPs by adsorption and could 
be released easily by diffusion. After this initial effect, a slower 
sustained and controlled release occurred throughout the release 
period at pH 6.8, and the release amount was 100% in both 
0.2%w/v and 0.25%w/v loaded cephalexin at 20 h. Other loaded 
concentrations as 0.05%w/v, 0.1% w/v and 0.15%w/v their release 
at 26h were 38%, 50% and 66% respectively. The release profiles 
indicated that cephalexin molecules were encapsulated among the 
positively charged chitosan chains, also high antibiotic loaded 
concentrations in CSNPs reflect accepted complete release during 
26h.
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Fig. 6: % Release of cephalexin loaded in CS nano carriers (n=3; mean±SD) 
 
Release kinetics study 
The data of the release of the cephalexin from the nanocomposites 
were fitted to six kinetic models, which are described as shown in 
table 4. The results indicated that the release of most antibiotic 
concentrations from the nanocomposites followed diffusion kinetic 
model, with a best fit value for the correlation coefficient (R2) at 
0.9761. The rate of drug release from any solid or semi-solid delivery 
system is usually controlled by dissolution and/or diffusion. 
Regardless of mechanisms involved in the release, its rate under sink 
conditions can be expressed by a single general equation as follows:  
 
W is amount of drug released up to time t and dw/dt is the rate of 
release. D, S, Cs and h are drug molecule diffusion coefficient, 
effective surface area of drug with release medium, drug solubility in 
the medium and the length of diffusion path. This equation 
represents both the Noyes-Whitney law of dissolution [45], applied 
for dissolution rate limited release as well as the Fick’s first law of 
diffusion used for diffusion rate limited release processes [46]. In 
the dissolution process h, the thickness of stagnant aqueous layer 
around drug particle is constant but S and sometimes D are varied 
during the release process [47]. On the other hand in a diffusion rate 
limited release in addition to D, h and sometimes S are variable 
during the release process. For a complex system such as 
nanoparticles the previous equation does not seem to include all 
other factors influencing the release rate among which penetration 
rate of liquid into the system; hydration, swelling, relaxation, 
erosion and dissolution of polymer can be mentioned. The extents of 
liquid penetration and the polymer contributed properties are 
directly proportional to t1/2 and powered of t, respectively. Thus, 
these effects are collectively represented as a time dependent 
variable, X, and the equation becomes:  
 
Therefore, regardless of release mechanism in order to obtain a 
general working formula for both dissolution and diffusion rate 
limited release processes it is assumed that the term DSX/h is 
variable during the release. 
 
Table 4: Data fitting for cephalexin release from cephalexin-CSNPs using six different 
 Zero First Second Diffusion Hixon Baker  
a 13.66772 1.725437 0.010341 1.360582 0.217743 0.002237  
b 0.030174 3.8E-05 7.75E-06 1.393847 0.000599 3.97E-05 chosen "r" 
r 0.906972 0.043844 0.816441 0.976108 0.927012 0.973077 0.976108 
k 0.030174 8.75E-05 7.75E-06 1.393847 0.000599 3.97E-05  
t(1/2) 45 7920.455 1290.394 1286.796 1595.407 1387.085  
 
Table 5: Six month stability studies of optimized unloaded nano-carriers at different temperature 







PDI 0.311±0.103  0.297±0.052 
Zeta potential±SD 20.05±2.317  18.174±5.379 
Optimum-loaded formula mo 1 mo 2  mo 3 mo 4 mo5 mo6 mean±SD 
TEM size 
Zeta size 
42.6 46.2  50.1 49.4 55.5 54.3 49.7±4.8 
205.9 216.8  204.5 233 242.1 245.5 224.633±18.0 
PDI 0.216 0.341  0.284 0.382 0.341 0.332 0.349±0.04 
Zeta potential  24.7 24.1  22 17.5 18.6 20.2 19.516±3.3 
EE% 
Drug loading 
93.531 92.685  94.429  96.663 95.315 95.421 94.674±1.4 
43.521 42.192  42.921  43.937 43.9 42.8 43.061±0.6 
Retention value % 100 99.095  98.313 96.223 96.00 96.00 97.605±1.7 
Six month stability studies of Nano-carriers loaded with cephalexin 0.25%w/v 
All data presented as mean±SD  
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Stability study of cephalexin CSNPs 
Table 5 clarify the optimized plane formula measured monthly for six 
month at two different temperature. The average Nano size at 25C ° 
was 287±81.156 nm, and that at 4 C °was 184.36±25.276. The PDI was 
about 0.2 and no significant change in Zeta potential. The average 
Nano size measured by TEM was 30±15. Indicating stable CSNPs 
carriers especially stored at low temperature. Six month tested loaded 
formula showed average Nano size measured by TEM was 49.7±4.8, 
average size measured by Zeta sizer was 224.633±18, PDI was 
0.349±0.04, Zeta potential was 19.516±3.3, mean EE% was 
94.674±1.4, drug loading was 43.061±0.6 and drug retention value % 
of six month storage was 97.605±1.7. These results emphasize that 
either plane or loaded CSNPs carriers are fairly stable over six month 
stability studies. 
Antibacterial activity 
Chitosan has been identified as an antimicrobial agent against 
various microorganisms [48]. CSNPs have gained growing interest 
due to its biocompatibility, biodegradability, high permeability, cost-
effectiveness, non-toxic property and excellent film forming ability. 
Moreover, its ability to enhance the penetration of large molecules 
across a mucosal surface and its recognition as mucoadhesive agent 
[49, 50]. However, the evaluation of CSNPs antibacterial activity has 
rarely been reported. The unique character of CSNPs i.e. very small 
quantum size exhibit them superior activities [51]. In the present 
study the antibacterial activity CSNPs (1250µg/ml) and cephalexin 
loaded CSNPs (250 µg/ml cephalexin loaded in 1250 µg/ml CSNPs) 
was evaluated and compared to a reference; cephalexin antibiotic 
(1000 µg/ml) by microdilution method (table 6) against different 
Gram-positive and Gram-negative bacterial strains. Both CSNPs and 
cephalexin loaded CSNPs showed good antimicrobial activity against 
Gram-positive and Gram negative bacteria. However cephalexin 
loaded CSNPs showed higher antimicrobial activity than plain 
CSNPs. Nevertheless, it is worth pointing out that synergistic effects 
were found against S. aureus (ATCC 25923), B. subtilis (ATCC 9372), 
S. epidermidis and E. faecalis
Regarding the effectiveness of both formulas against Gram-negative 
bacterial strains; cephalexin loaded CSNPs displayed synergistic 
effects against P. aeruginosa (ATCC 29853) and against two 
carbapenem resistant isoletes (
. MIC of Cephalexin in CSNPs 
combination was 31.25, 3.9, 3.9 and 31.25 µg/ml respectively. There 
was a great reduction in MIC values for cephalexin loaded CSNPs 
compared to plain Cephalexin. Additionally cephalexin loaded CSNPs 
showed higher bactericidal activity against S. epidermidis 
(78.5µg/ml) and 312.5 µg/ml for other Gram positive strains. These 
results were comparable to a many studies that comparing the 
activity of plain chitosan nanoparticle to antibiotics loaded 
nanoparticles. A study by Saha et al. [52], demonstrated superior 
antimicrobial activity and synergistic effect of ampicillin trihydrate 
loaded chitosan nanoparticles compared to both plain nanoparticles 
and reference antibiotics. Moreover Xu et al. [53]. Prepare 
vancomycin loaded chitosan nanoparticles that displayed a lower 
MIC value than plain vancomycin (80 to 60 µg/ml) against S. aureus 
that corresponds to higher antibacterial effectiveness. In the same 
line Ibrahim et al. [54], in Egypt prepare chitosan nanoparticles to 
improve intracellular delivery of some poorly cell-penetrating 
antibiotic e. g. Ciprofloxacin, Chlortetracycline hydrochloride and 
Gentamycin sulfate and reported an increase in antibacterial activity 
of loaded chitosan nanoparticles against Gram-positive (S. aureus) 
bacteria rather than Gram-negative (E. coli) bacteria. In the current 
study plain CSNPs found to have antibacterial inhibitory effect 
against S. aureus (ATCC 25923) (MIC, 312.5) and E. faecalis (MIC, 
312.5 better than the reference antibiotic (MIC ˃500). This result 
was comparable to Thaya, et al. [55], who reported that chitosan-
alginate microspheres exhibited effective growth inhibition against 
S. aureus, E. faecalis more than P. aeruginosa and Proteus vulgaris by 
disk diffusion method.  
k. pneumoniae
Conversely, a relatively poor antibacterial activity shown for E. coli 
(ATCC 25922) may be related to decreased charge compactness, 
which established with the surface charge classification of ‘slightly 
charged’ [59]. Generally, the antimicrobial effectiveness of chitosan 
against Gram-positive and Gram-negative bacteria is fairly 
contentious. In some published works, a predominant effectiveness 
against Gram-positive strains is documented. Although the 
interaction between positively charged chitosan groups and 
negatively charged microbial cell is assumed as the main 
antimicrobial mechanism [60, 61], the thick peptidoglycan layer 
provide a barrier against chitosan interactions. While the Gram-
negative cell wall is thinner and consequently more susceptible to 
chitosan derivatives than the Gram-positive’s bacterial strains [62, 
63]. Positively charged chitosan easily interfere with negatively 
charged bacterial cell membrane that is may be the hopeful 
mechanism for the bactericidal characters [55]. 
 and E. coli clinical 
isolates); MIC values were 31.25, 3.9 and 31.25 µg/ml respectively 
which is also far different compared to plain Cephalexin. On the 
other hand antagonistic effect was found against E. coli (ATCC 
25922). The MIC of cephalexin loaded CSNPs against E. coli (ATCC 
25922) was 31.25 µg/ml while it was 15.625 µg/ml for plain 
cephalexin which indicated antagonism. The MBC value of 
cephalexin loaded CSNPs was 312.5 µg/ml for all Gram negative 
bacteria except E. coli (ATCC 25922) was 625 µg/ml. These results 
were consistent with various recent studies such as Kanchana et al. 
[56], whose antibacterial activity results demonstrates a lower MIC 
values for antibiotics (ampicillin trihydrate and cephalexin) 
encapsulated chitosan nanoparticles than pare antibiotics against 
Escherichia coli and Klebsiella pneumoniae causing urinary tract 
infection. Also Plain CSNPs displayed antibacterial inhibitory effect 
against E. coli and Pseudomonas aeruginosa (MIC, 312.5 and 
312.5respectively) better than the reference antibiotic (MIC, ˃500). 
Our results agreed with Divya et al. [57], who reported high 
antimicrobial activity of chitosan nanoparticles (5000 µg/ml) 
against medical pathogens Klebsiella pneumoniae, Escherichia coli, 
Staphylococcus aureus and Pseudomonas aeruginosa. Furthermore 
Tamara et al. [58], indicated that the chitosan/protamine 
nanoparticles have improved antibacterial activity towards 
pathogenic E. coli rather than probiotic B. cereus.  
 
Table 6: MIC and MBC of cephalexin, CSNPs, and cephalexin loaded CSNPs against different microorganisms 
M. O Cephalexin (µg/ml) CSNPs (µg/ml) Cephalexin (µg/ml) loaded in CSNPs Ʃ FIC 
Gram-positive bacteria MIC MBC MIC MBC MIC MBC 
S. aureus (ATCC 25923) ˃500 ˃500 312.5 625 31.25 312.5 0.562 Synergism 
B. subtilis (ATCC 9372) 15.625 500 156.25 625 3.9 312.5 0.37 Synergism 
S. epidermidis 62.5 500 78.5 156.25 3.9 78.5 0.311 Synergism 
˃500 E. faecalis ˃500 312.5 625 31.25 312.5 0.562 Synergism 
Gram-negative bacteria 
E. coli (ATCC 25922). 15.625 125 312.5 625 31.25 625 2.18 Antagonism 
P. aeruginosa (ATCC 
29853). 
˃500 ˃500 312.5 625 31.25 312.5 0.562 Synergism 
15.625 k. pneumoniae 250 156.25 625 3.9 312.5 0.37 Synergism 
E. coli ˃500 ˃500 312.5 ˃625 31.25 312.5 0.562 Synergism 
 
Biofilm inhibition assay  
Pathogenic microorganisms produce biofilm by synthesizing 
exopolysaccharides which enable bacterial adhering to the surfaces 
and protects the microbes from the harsh environment [64]. Biofilm 
producers microorganisms are the major cause of prosthetic device 
related infections. Though it is a major medical problem, much work 
has not been performed in this respect [65]. Most of the research 
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studies focusing on action of chitosan against planktonic 
microorganisms, but restricted information is known about its activity 
upon bacterial adhesion and biofilm formation [69]. In current work; 
screening of biofilm production of tested microorganisms by culturing 
onto CRA plate (Fig: 7a) revealed that two multidrug resistant clinical 
isolates (klebsiella pneumoniae and Enterococcus faecalis) were biofilm 
producers, accordingly, the antibiofilm activity of CSNPs and 
cephalexin loaded CSNPs in their sub MIC conc. were tested against 
both microorganisms by tube assay. Results showed that cephalexin 
loaded in CSNPs displayed antibiofilm activity in its sub MIC 
concentration (62.5 µg/ml) against Enterococcus faecalis (Fig: 7b) and 
no antibiofilm activity was detected against klebsiella pneumoniae 
clinical isolate in sub MIC (7.8 µg/ml) of cephalexin loaded in 
CSNPs. These results were agreed with study by Thaya, et al. [55], who 
reported that chitosan-alginate microspheres exhibited antibiofilm 
effect against S. aureus, E. faecalis P. aeruginosa and P. vulgaris 
respectively, also another study by Costa et al. [66], investigated the 
antibiofilm activity of chitosan on periodontal bacteria and both 
studies showed that chitosan has antibiofilm activity with high 
inhibition rate against specified pathogens. Moreover Divya and Jisha 
[64], investigated the antibiofilm activity of chitosan nanoparticles 
against K. pneumoniae, E. coli, S. aureus, P. aeruginosa clinical 
isolates. This antibiofilm activity
MTT cytotoxicity assay 
 could be correlated to inhibition of 
exopolysaccharide synthesis resulting in reduction of biofilm 
formation [67]. Also the aforementioned activity may be associated 
with the diffusion of nanoparticles through the channels in biofilm 
structure [68]. 
The MTT assay measures the cell metabolic activity, which is directly 
proportional to cell numbers under appropriate culture conditions. 
The percentages of viable cells were determined in relation to the 
control cells fig. (8). Cytotoxic effects of CSNPs and cephalexin loaded 
CSNPs on WI-38 fibroblasts cells proliferation, viability and IC50 were 
carried out by MTT cytotoxicity assay (table 7). The results revealed 
that cephalexin loaded CSNPs has lower cytotoxicity compared to 
plain CSNPs. The half maximal inhibitory concentration (IC50 which is 
defined as the drug concentration needed to kill 50% of the incubated 
cells in a specific time) of cephalexin loaded CSNPs was 231.893 while 
for CSNPs IC50 was 18.597. The viability of cells was 99.25% and 38.2 
% at 23.4(3.9+19.53) µg/ml conc. of cephalexin loaded CSNPs and 
CSNPs respectively. Fig. (9 and 10). These results were in agreement 
with previous studies as a study by Xu et al. [53], where Vancomycin-
Loaded N-trimethyl chitosan nanoparticle showed significantly higher 
cell proliferation activity compared with vancomycin solutions. Also 
Hussein et al. [38], reported that the highest concentrations of plain 
drug and drug loaded-CSNPs (100 µg/ml) resulted in 78.2 and 62.4% 
cells viability, respectively. This proliferative effect is complemented 
by nanostructure, biocompatibility and fixed surface structure in the 
nanometer size scale [69]. On the other hand, Salarian et al. [70], 
perform MTT assay for cephalexin alone at different concentrations 
and no cytotoxicity was detected even at a high concentration of 5000 
mg/ml confirming that highly concentrated non-toxic cephalexin could 
be applied as effective treatment even at higher dosages. 
  
 
2TFig.2T 7A: CRA plates showed black dry crystalline colonies of 2TEnterococcus faecalis (a) and klebsiella pneumoniae(b), B: biofilm tube assay 
for2T4T 2T4TEnterococcus faecalis (a): negative control, (b): positive control, (c):2T CSNPs and (d): cephalexin loaded CSNPs 
 
Table 7: MTT cytotoxicity assay profile showing Viability %, toxicity % and IC50 of control, CSNPs and cephalexin loaded CSNPs. The 
percentages of viable cells were expressed relative to the control cells (WI-38 fibroblasts) 
ID Conc. µg/ml Optical density (OD) Mean OD STD Viability % Toxicity % IC50 
Wi-38 0.256 0.264 0.257 0.259 0.002517 100 0  
 
CSNPs 
750 0.016 0.024 0.018 0.019333 0.002404 7.464607465 92.53539254  
18.597 375 0.026 0.031 0.025 0.027333 0.001856 10.55341055 89.44658945 
187.5 0.053 0.06 0.058 0.057 0.002082 22.00772201 77.99227799 
93.75 0.06 0.077 0.071 0.069333 0.004978 26.76962677 73.23037323 
46.875 0.094 0.088 0.087 0.089667 0.002186 34.62033462 65.37966538 
23.438 0.1 0.099 0.098 0.099 0.000577 38.22393822 61.77606178 
11.718 0.175 0.156 0.158 0.163 0.006028 62.93436293 37.06563707 









0.052 0.064 0.059 0.058333 0.00348 22.52252252 77.47747748 
187.5 
31.25+156.25 
0.124 0.133 0.128 0.128333 0.002603 49.54954955 50.45045045 
93.75 
15.6+78.125 
0.205 0.216 0.209 0.21 0.003215 81.08108108 18.91891892 
46.8 
7.8+39.06 
0.241 0.25 0.246 0.245667 0.002603 94.85199485 5.148005148 
23.46 
3.9+19.53 
0.254 0.256 0.261 0.257 0.002082 99.22779923 0.772200772 
The results are presented as mean±SD  
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Fig. 9(A and B): Toxicity effect of CSNPs on WI-38 cells at different concentrations 
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Fig. 10(A, B): Toxicity effect of cephalexin loaded CSNPs on WI-38 cells at different concentrations 
 
CONCLOSION 
Cephalexin-chitosan nanocomposites were successfully prepared with 
simple method and good combination. Nano-particles criteria were 
suitable in addition to drug loaded and release. Formulas proved long 
term stabilityCephalexin loaded CSNPs showed synergistic effects 
against seven of studied bacterial strains including two carbapenem 
resistant isolates. Also it exhibit antibiofilm activity against E. faecalis 
clinical isolate and had minimized cytotoxicity. 
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